A Phase II Trial to Evaluate Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Latest Information Update: 17 Mar 2025
At a glance
- Drugs Abemaciclib (Primary) ; Anastrozole (Primary) ; Estradiol (Primary) ; Exemestane (Primary) ; Fludeoxyglucose F-18 (Primary) ; Fulvestrant (Primary) ; Gonadotropin releasing hormone (Primary) ; Letrozole (Primary) ; Tamoxifen (Primary)
- Indications HER2 negative breast cancer; Male breast cancer
- Focus Therapeutic Use
Most Recent Events
- 12 Mar 2025 Planned End Date changed from 1 Jun 2026 to 1 Jun 2028.
- 12 Mar 2025 Planned primary completion date changed from 1 Mar 2025 to 1 Mar 2027.
- 16 Jan 2025 Status changed from suspended to recruiting.